



# EXTRAORDINARY TECHNOLOGY

ID NOW™ is the fastest  
point of care molecular  
platform on the market<sup>1</sup>

ID NOW™ utilizes proven isothermal molecular technology in an intuitive platform, providing the fastest highly sensitive molecular results in the market at 2 to 13 minutes!<sup>1</sup>


The use of thermocycling, a series of temperature changes, is utilized by PCR, a conventional method, to amplify DNA. This heating and cooling adds time to result.

ID NOW utilizes isothermal technology, a proven next-generation molecular technology that uses proprietary enzymes and constant temperature, to achieve the fastest available DNA amplification.

MOLECULAR TECHNOLOGY	PCR	ID NOW
Target	DNA/RNA	DNA/RNA
Common Detection Method	Molecular Beacon	<b>Molecular Beacon</b>
Amplification	Yes	<b>Yes</b>
Method to open DNA	Heat	<b>Enzyme</b>
Requires thermocycling	Yes	<b>No</b>
Time to results	15 min-hours	<b>&lt;/= 13 minutes</b>

## THE IDEAL MOLECULAR PLATFORM FOR POINT OF CARE

Tests are quickly and easily performed, without complex pipetting, using color-coded, intuitive, and self-contained instrumentation and reagents.



## TIMELY RESULTS. TIMELY DECISIONS



### SPEED TIME TO TREATMENT

Improve patient care and mortality rates<sup>2,3</sup>



### APPROPRIATE USE OF OTHER TESTING

Reduce unnecessary imaging, blood and urine cultures, etc.<sup>3,8</sup>



### OPTIMIZE WORKFLOW & PATIENT THROUGHPUT

Shorten wait times & length of stay<sup>2,5</sup>  
Median patient visit time is 15.7 minutes<sup>6</sup>



### APPROPRIATE ADMISSIONS

Reduce unnecessary admissions and improve bed management<sup>5</sup>



### EFFICIENT USE OF ISOLATION RESOURCES & PROCEDURES

Reduce hospital infection & outbreak rates<sup>12</sup>



### ANTIBIOTIC STEWARDSHIP

Decrease unnecessary antibiotic use<sup>3,4,8</sup>  
Reduction in adverse drug reactions<sup>2</sup>



### EFFICIENT USE OF TESTING RESOURCES

Faster time to results may lead to shorter operational time and instrumentation needed

## Maximize your testing space





## AVAILABLE TESTS

**ID NOW<sup>™</sup> INFLUENZA A & B 2**  
RESULTS IN 5-13 MINUTES<sup>9,10</sup>  
CPT<sup>®</sup> 87502

**ID NOW<sup>™</sup> STREP A 2**  
RESULTS IN 2-6 MINUTES<sup>11,12</sup>  
CPT<sup>®</sup> 87651

**ID NOW<sup>™</sup> RSV**  
RESULTS IN 13 MINUTES OR LESS<sup>13</sup>  
CPT<sup>®</sup> 87634

\*Nasal swab directs only

## ORDERING INFORMATION

PRODUCT NAME	PRODUCT CODE
<b>ID NOW<sup>™</sup> Instrument</b>	NAT-024
<b>ID NOW<sup>™</sup> Influenza A &amp; B 2 24 Test Kit</b>	427-000
<b>ID NOW<sup>™</sup> STREP A 2 24 Test Kit</b>	734-000
<b>ID NOW<sup>™</sup> RSV 24 Test Kit</b>	435-000

1. Abbott Press Release: Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
2. Barenfager, *et al.* Clinical and Financial Benefits of Rapid Detection of Respiratory Viruses: an Outcomes Study. *J Clin Microbiol*, 2000 Aug; 38(8): 2824–2828.
3. Mackie, *et al.* Evaluation of an acute point-of-care system screening for respiratory syncytial virus infection. *Journal of Hospital Infection* (2001) 48: 66–71.
4. Bonner, A.B. *et al.* Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Mgmt in the Pediatric ED: Results of a Randomized, Prospective, Controlled Trial. *Pediatrics*. 2003 Vol.112 No. 2.
5. Mills, *et al.* Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. *Journal of Hospital Infection* 77 (2011) 248-251.
6. Tai-Seale, *et al.* Physician and Patient Behavior. Time Allocation in Primary Care Office Visits. *Health Serv Res*. 2007 Oct;42(5):1871–1894
7. Popow-kraupp, *et al.* Diagnosis of Respiratory Syncytial Virus Infection. *Open Microbiol J*. 2011; 5: 128–134.
8. Chartrand, *et al.* 2015. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. *J Clin Microbiol*, 2015; 53(12): 3738 –3749.
9. Moore N, *et al.* Evaluation of the ID NOW<sup>™</sup> Influenza A & B 2 Assay. 2018 ASM Clinical Virology Symposium, West Palm Beach, FL. Poster.
10. ID NOW Influenza A & B 2 Product Insert
11. ID NOW<sup>™</sup> Strep A 2 clinical assertion data, held on file
12. ID NOW<sup>™</sup> Strep A 2 Product Insert
13. ID NOW<sup>™</sup> RSV Product Insert

**LEARN MORE ABOUT ID NOW MOLECULAR TECHNOLOGY.  
CONTACT YOUR ABBOTT ACCOUNT EXECUTIVE.**

© 2019 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. IDDM151310 120004614-01 08/19

